Bio-Path Holdings, Inc. – NASDAQ:BPTH

Add to watchlist

$0.1

-1.03

-91.23%

Market closed

Open in about 1 hour

-41.84%

month

-41.84%

quarter

+121.49%

year

Market Cap	4.78M
Enterprise value	459.96K

P/E	-0.75
EV/Sales	N/A
EV/EBITDA	-0.04
Price/Sales	N/A
Price/Book	0.74
PEG ratio	0.03
EPS	-27.34

Revenue	N/A
EBITDA	-13.79M
Income	-13.96M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Bio-Path Holdings, Inc. (NASDAQ:BPTH): Profit margin
Jun 2023	0	-4.23M
Sep 2023	0	-3.19M
Dec 2023	274K	-3.37M	-1230.66%
Mar 2024	0	-3.15M

Bio-Path Holdings Financials Estimate

Q Y

Bio-Path Holdings, Inc. (NASDAQ:BPTH): Analyst Estimates
2025	21.60M	-14.07M	-65.14%
2026	40.05M	-14.24M	-35.57%
2027	39.84M	-1.62M	-4.08%
2028	58.20M	2.48M	4.26%

Analysts Price target
Financials & Ratios estimates

Bio-Path Holdings, Inc. (NASDAQ:BPTH): Debt to assets
Jun 2023	6524000	1.48M	22.7%
Sep 2023	5021000	2.49M	49.71%
Dec 2023	3220000	2.77M	86.3%
Mar 2024	1768000	4.39M	248.47%

Bio-Path Holdings, Inc. (NASDAQ:BPTH): Cash Flow
Jun 2023	-3.28M	0
Sep 2023	-2.78M	1.68M
Dec 2023	-1.81M	514K
Mar 2024	-1.03M	174K

Bio-Path Holdings alternative data

Bio-Path Holdings, Inc. (NASDAQ:BPTH): Employee count
Aug 2023	10
Sep 2023	10
Oct 2023	10
Nov 2023	10
Dec 2023	10
Jan 2024	10
Feb 2024	10
Mar 2024	10
Apr 2024	10
May 2024	10
Jun 2024	10
Jul 2024	10

Bio-Path Holdings
Hedge Funds Holdings Q1 2023

1.68% -7.35%

of BPTH is owned by hedge funds

13 -5

hedge funds hold BPTH stock

122.06K -524.39K

shares is hold by hedge funds

BPTH hedge funds holdings changes

Bio-Path Holdings
Insider Trading

Bio-Path Holdings, Inc. (NASDAQ:BPTH): Insider trades (number of shares)
Period	Buy	Sel
Jan 2019	0	64457

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	18 Jan 2019	ARMISTICE CAPITAL, LLC 10 percent owner 10 percent owner	Common Stock	64,457	$2.66	$171,649
Purchase	13 Jul 2015	GARRISON MICHAEL J. director director	Common Stock	7,343	$1.22	$8,958
Purchase	9 Jul 2015	GARRISON MICHAEL J. director director	Common Stock	8,724	$1.17	$10,207
Purchase	8 Jul 2015	GARRISON MICHAEL J. director director	Common Stock	21,015	$1.2	$25,218
Purchase	7 Jul 2015	GARRISON MICHAEL J. director director	Common Stock	38,985	$1.18	$46,002
Purchase	12 Jun 2013	GARRISON MICHAEL J. director director	Common Stock	340,000	$0.3	$102,000
Purchase	2 Dec 2009	GARRISON THOMAS E director director	warrant	350,000	$0.25	$87,500
Purchase	2 Dec 2009	GARRISON THOMAS E director director	common stock	350,000	$0.25	$87,500
Purchase	13 Oct 2009	GARRISON THOMAS E director director	common stock	400,000	$0.25	$100,000
Purchase	13 Oct 2009	GARRISON THOMAS E director director	warrant	400,000	$0.25	$100,000

BPTH insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application P-ETHOXY NUCLEIC ACIDS FOR IGF-1R INHIBITION Filling date: 18 Nov 2021 Issue date: 5 May 2022	18 Nov 2021	5 May 2022
Application	Application P-ETHOXY NUCLEIC ACIDS FOR STAT3 INHIBITION Filling date: 4 Jun 2021 Issue date: 28 Apr 2022	4 Jun 2021	28 Apr 2022
Application	Application P-ETHOXY NUCLEIC ACIDS FOR LIPOSOMAL FORMULATION Filling date: 18 Dec 2020 Issue date: 25 Nov 2021	18 Dec 2020	25 Nov 2021
Application	Application COMBINATION THERAPY WITH LIPOSOMAL ANTISENSE OLIGONUCLEOTIDES Filling date: 15 Jan 2021 Issue date: 26 Aug 2021	15 Jan 2021	26 Aug 2021
Grant	Grant Utility: P-ethoxy nucleic acids for STAT3 inhibition Filling date: 19 Apr 2018 Issue date: 22 Jun 2021	19 Apr 2018	22 Jun 2021
Application	Application P-ETHOXY NUCLEIC ACIDS FOR BCL2 INHIBITION Filling date: 19 Apr 2018 Issue date: 29 Apr 2021	19 Apr 2018	29 Apr 2021
Application	Application P-ETHOXY NUCLEIC ACIDS FOR IGF-1R INHIBITION Filling date: 19 Apr 2018 Issue date: 22 Apr 2021	19 Apr 2018	22 Apr 2021
Grant	Grant Utility: Combination therapy with liposomal antisense oligonucleotides Filling date: 15 Sep 2017 Issue date: 23 Feb 2021	15 Sep 2017	23 Feb 2021
Grant	Grant Utility: P-ethoxy nucleic acids for liposomal formulation Filling date: 30 May 2019 Issue date: 26 Jan 2021	30 May 2019	26 Jan 2021
Application	Application P-ETHOXY NUCLEIC ACIDS FOR LIPOSOMAL FORMULATION Filling date: 30 May 2019 Issue date: 16 Apr 2020	30 May 2019	16 Apr 2020

Bio-Path Holdings
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 15 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 8 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 15 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 15 Aug 2023	Q2 2023 Earnings Call Transcript

BPTH earnings call transcripts

Bio-Path Holdings
Executives

Insider	Age	Since	Compensation
Mr. Peter H. Nielsen MBA (1949) Co-Founder, Chairman, Chief Executive Officer, Pres, Chief Financial Officer & Treasurer	76		$660,170
Mr. Douglas P. Morris (1956) Co-Founder, Director of Investor Relations, Sec. & Director	69		$50,640

Bio-Path Holdings
Latest News

Thursday, 19 December 2024
07:00	Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity	globenewswire.com
Friday, 13 December 2024
16:44	Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24	newsfilecorp.com
Wednesday, 11 December 2024
07:00	Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients	globenewswire.com
Wednesday, 20 November 2024
13:00	All You Need to Know About Bio-Path (BPTH) Rating Upgrade to Buy	zacks.com
10:55	Bio-Path (BPTH) Could Find a Support Soon, Here's Why You Should Buy the Stock Now	zacks.com
Friday, 15 November 2024
09:26	Bio-Path Holdings, Inc. (BPTH) Q3 2024 Earnings Call Transcript	seekingalpha.com
07:00	Bio-Path Holdings Reports Third Quarter 2024 Financial Results	globenewswire.com
Friday, 8 November 2024
07:00	Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024	globenewswire.com
Thursday, 10 October 2024
17:24	Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules	globenewswire.com
Tuesday, 8 October 2024
20:00	Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules	globenewswire.com
07:00	Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity	globenewswire.com
Wednesday, 4 September 2024
17:48	Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 24	newsfilecorp.com
Tuesday, 3 September 2024
07:00	Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference	globenewswire.com
Thursday, 15 August 2024
07:00	Bio-Path Holdings Reports Second Quarter 2024 Financial Results	globenewswire.com
Thursday, 8 August 2024
07:00	Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024	globenewswire.com
07:00	Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024	globenewswire.com
Monday, 8 July 2024
07:00	Bio-Path Holdings Provides Clinical Update and Expansion Plans	globenewswire.com
Friday, 14 June 2024
11:30	Why Is Bio-Path (BPTH) Stock Up 20% Today?	investorplace.com
07:00	Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress	globenewswire.com
Wednesday, 5 June 2024
17:46	Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules	globenewswire.com
Tuesday, 4 June 2024
16:55	Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24	newsfilecorp.com
Monday, 3 June 2024
07:00	Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting	globenewswire.com
Friday, 24 May 2024
07:00	Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress	globenewswire.com
Thursday, 23 May 2024
17:00	Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting	globenewswire.com
Wednesday, 15 May 2024
11:04	Bio-Path Holdings Inc. (BPTH) Q1 2024 Earnings Call Transcript	seekingalpha.com
07:00	Bio-Path Holdings Reports First Quarter 2024 Financial Results	globenewswire.com
Wednesday, 8 May 2024
07:00	Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024	globenewswire.com
Friday, 19 April 2024
12:14	Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	globenewswire.com
11:16	Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study	Zacks Investment Research
Thursday, 18 April 2024
10:28	Why Is Bio-Path (BPTH) Stock Up 89% Today?	InvestorPlace

Frequently Asked Questions (FAQ)

What's the price of Bio-Path Holdings stock today?

One share of Bio-Path Holdings stock can currently be purchased for approximately $0.1.
When is Bio-Path Holdings's next earnings date?

Unfortunately, Bio-Path Holdings's (BPTH) next earnings date is currently unknown.
Does Bio-Path Holdings pay dividends?

No, Bio-Path Holdings does not pay dividends.
How much money does Bio-Path Holdings make?

Bio-Path Holdings has a market capitalization of 4.78M.
What is Bio-Path Holdings's stock symbol?

Bio-Path Holdings, Inc. is traded on the NASDAQ under the ticker symbol "BPTH".
What is Bio-Path Holdings's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Bio-Path Holdings?

Shares of Bio-Path Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Bio-Path Holdings's key executives?
Bio-Path Holdings's management team includes the following people:
- Mr. Peter H. Nielsen MBA Co-Founder, Chairman, Chief Executive Officer, Pres, Chief Financial Officer & Treasurer(age: 76, pay: $660,170)
- Mr. Douglas P. Morris Co-Founder, Director of Investor Relations, Sec. & Director(age: 69, pay: $50,640)
Is Bio-Path Holdings founder-led company?

Yes, Bio-Path Holdings is a company led by its founders Mr. Peter H. Nielsen MBA and Mr. Douglas P. Morris.
How many employees does Bio-Path Holdings have?

As Jul 2024, Bio-Path Holdings employs 10 workers.
When Bio-Path Holdings went public?

Bio-Path Holdings, Inc. is publicly traded company for more then 17 years since IPO on 4 Mar 2008.
What is Bio-Path Holdings's official website?

The official website for Bio-Path Holdings is biopathholdings.com.
Where are Bio-Path Holdings's headquarters?

Bio-Path Holdings is headquartered at 4710 Bellaire Boulevard, Bellaire, TX.
How can i contact Bio-Path Holdings?

Bio-Path Holdings's mailing address is 4710 Bellaire Boulevard, Bellaire, TX and company can be reached via phone at 832 742 1357.

Bio-Path Holdings, Inc.

biopathholdings.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

832 742 1357

4710 Bellaire Boulevard
Bellaire, TX 77401

CIK: 0001133818
ISIN: US09057N3008
CUSIP: 09057N300